
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Trametinib is a broad-spectrum anti-cancer drug.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:97
Patients with unresectable or metastatic melanoma with BRAF V600E mutation.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:107
Thrombocytopenia in patients with chronic liver disease and chronic immune disorders.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:166
Cabozantinib has been approved for the treatment of various cancers.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:168
Suitable for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFRT790M mutation positivity.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:34
Treat thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:150
Crizotinib is suitable for the treatment of non-small cell lung cancer.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:105
Finerenone is applicable to chronic kidney disease related to type 2 diabetes.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:165
Mitotane is used for treatment Adrenal cortex carcinoma.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:116
Cibinqo can treat atopic dermatitis.【more】
Article source:Captain MedicineRelease date:2026-01-06Recommended:125
Broad-spectrum antitumor agents【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:121
KRAS G12C mutation in non-small cell lung cancer and colorectal cancer【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:143
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】
Recommended:[list:visits]2026-24-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended:[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended:[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended:[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended:[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended:[list:visits]2026-16-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643